The discovery and development of new drugs is very costly and attrition rates are high. Initiatives to reduce the rate of attrition during later phases are clearly desirable and if successfully implemented will reduce development costs. The InnoMed proposal addresses the complex issues associated with the future of biomédical research in the EU, and addresses ways of achieving accelerated development of, safe and more effective medicines, aiming to revitalize the European biopharmaceutical research environment. InnoMed's wide consortium base, being led by the European Federation of Pharmaceutical Industry and Associations (EFPIA), guarantee's a commitment from all the stakeholders needed to change the process of drug development in Europe. The course for addressing the necessary changes is to first develop a Strategic Research Agenda (SRA) that will encompass the whole path from discovery of a new drug target to the validation and approval stages of a new drug compound. This will be agreed by all the relevant stakeholders via meetings and workshops. Four key bottlenecks in the drug development process will be addressed: Safety Efficacy Knowledge Management Training and Education This comprehensive strategy with a detailed roadmap will lead to the deployment of a European Technology Platform (ETP). This European Technology Platform will deliver added value to the drug discovery and development process and to individual stakeholders. To ensure the relevance of the ETP InnoMed will validate it using two research proposals, AddNeuroMed, which will develop and validate novel surrogate markers based upon in vitro and in vivo models in animals and humans, using Alzheimer's disease as a testing platform. PredTox will deliver new biomarkers of toxicity and a greater understanding of mechanisms of toxicity. Both of these projects will demonstrate the viability and necessity of the ETP.
Call for proposal
See other projects for this call
Funding SchemeNoE - Network of Excellence